Doxorubicin Hexal Injection
Doxorubicin Hydrochloride
50mg/25ml
Novartis (Bangladesh) Ltd.
| Pack size | 1's pack |
|---|---|
| Unite Price | 1534.10 BDT |
Indications
Doxorubicin Hexal Injection is used for:
AIDS-related Kaposi's sarcoma, Ovarian carcinoma, Metastatic breast carcinoma, bladder carcinoma
Adult Dose
Intravenous
As Doxorubicin liposomal
Kaposi's Sarcoma
Indicated for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy
20 mg/m² IV q3Weeks
Ovarian Cancer
Indicated for ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy
50 mg/m² IV q4Weeks x 4 courses minimum
Multiple Myeloma
Indicated in combination with bortezomib for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy
30 mg/m² IV on day 4 following bortezomib 1.3 mg/m² on days 1, 4, 8 & 11 q3Weeks
Metastatic breast cancer
Adult: 60-75 mg/m2 BSA once every 3 wk in combination with cyclophosphamide given as an infusion over 1 hr diluted in 0.9% sodium chloride or 5% glucose.
Irrigation
Local malignant neoplasms in the bladder
Adult: 50 ml of a 1 mg/ml solution instilled into the bladder for 1 hr once a mth.
Hepatic Impairment
Serum bilirubin <1.2 mg/dL: Dose adjustment not necessary
Serum bilirubin 1.2-3 mg/dL [20.5-51.3 micromoles/L]: Give 50% dose
Serum bilirubin: 3.1-5 mg/dL [53-85.5 micromoles/L]: Give 25% dose
Severe hepatic impairment: Contraindicated
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment
Dose adjustment not necessary
Administration
Contra Indications
Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.
Precautions
Elderly, children, hepatic impairment. Monitor blood counts and ECG.
Lactation: Enters breast milk/not recommended
Pregnancy-Lactation
Pregnancy Category: D
Lactation: Enters breast milk/not recommended
Interactions
Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.
Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
Side Effects
Side effects of Doxorubicin Hydrochloride :
>10%
Kaposi's Sarcoma
Anemia (>50%), Thrombocytopenia (>50%), Neutropenia (10-50%), Anemia (18.2%), Nausea (17%)
Ovarian cancer
>25%
Hand-foot syndrome (50%), Nausea (46%), Stomatitis (41%), Asthenia (40.2%), Vomiting (32.6%), Rash (28%), Constipation (>25%), Abdominal pain (>25%)
Ovarian cancer
10-25%
Fever (21.3%), Anorexia (20%), Diarrhea (20%), Peripheral edema, Dyspepsia, Pharyngitis, Dyspnea, Alopecia
1-10%
Kaposi's Sarcoma
5-10%
Asthenia (9.9%), Fever (9.1%), Diarrhea (7.8%), Vomiting (7.8%), Stomatitis (6.8%), Rash (1-5%), Alopecia (1-5%), Increased alkaline phosphatase
Kaposi's Sarcoma
1-5%
Hand-foot syndrome (3.4%), Hypotension, Tachycardia, Dyspnea, Hemolysis, Rash
Ovarian cancer (selected)
Neutropenia (13.3%), Anemia (0.4-5.4%), Thrombocytopenia (1.3%)
<1%
Abscess, Acute myeloid leukemia, Cardiomegaly, Cardiomyopathy, Erythema nodosum, Hyperkalemia, Hyperuricemia, Ketosis
Potentially Fatal: Bone marrow suppression, cardiotoxicity.
Mode of Action
Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies.
Note
Doxorubicin Hexal 50mg/25ml Injection generic name is Doxorubicin Hydrochloride. Doxorubicin Hexal 50mg/25ml Injection is manufactured by Novartis (Bangladesh) Ltd.Doxorubicin Hexal is availble in all over Bangladesh.
Mes BD drug index information on Doxorubicin Hexal Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.